- Home
- RMTI vs ANL Comparison
RMTI vs ANL Comparison
Compare RMTI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- ANL
- Stock Information
- Founded
- RMTI 1994
- ANL 2004
- Country
- RMTI United States
- ANL Cayman Islands
- Employees
- RMTI N/A
- ANL N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- RMTI Health Care
- ANL
- Exchange
- RMTI Nasdaq
- ANL Nasdaq
- Market Cap
- RMTI 71.1M
- ANL 81.9M
- IPO Year
- RMTI 1998
- ANL 2023
- Fundamental
- Price
- RMTI $1.62
- ANL $2.29
- Analyst Decision
- RMTI Strong Buy
- ANL Strong Buy
- Analyst Count
- RMTI 2
- ANL 2
- Target Price
- RMTI $6.00
- ANL $9.00
- AVG Volume (30 Days)
- RMTI 201.6K
- ANL 8.6K
- Earning Date
- RMTI 03-20-2025
- ANL 03-18-2025
- Dividend Yield
- RMTI N/A
- ANL N/A
- EPS Growth
- RMTI N/A
- ANL N/A
- EPS
- RMTI N/A
- ANL N/A
- Revenue
- RMTI $98,917,000.00
- ANL $5,000,000.00
- Revenue This Year
- RMTI $22.58
- ANL N/A
- Revenue Next Year
- RMTI N/A
- ANL N/A
- P/E Ratio
- RMTI N/A
- ANL N/A
- Revenue Growth
- RMTI 22.37
- ANL N/A
- 52 Week Low
- RMTI $1.35
- ANL $1.85
- 52 Week High
- RMTI $5.15
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- RMTI 41.26
- ANL 54.82
- Support Level
- RMTI $1.49
- ANL $2.05
- Resistance Level
- RMTI $1.74
- ANL $2.42
- Average True Range (ATR)
- RMTI 0.11
- ANL 0.15
- MACD
- RMTI 0.00
- ANL 0.01
- Stochastic Oscillator
- RMTI 44.12
- ANL 57.45
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.